Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug
Portfolio Pulse from Priya Nigam
Shares of Neumora Therapeutics Inc (NASDAQ:NMRA) were trading lower on Tuesday, a month after the company's IPO. Analysts from RBC Capital Markets, Stifel, and William Blair initiated coverage with Outperform and Buy ratings, and price targets of $24 and $26 respectively. The analysts are bullish about the company's lead drug navacaprant for major depressive disorder (MDD), despite the stock's recent performance.
October 10, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are bullish on Neumora Therapeutics' lead drug for MDD, despite the stock's recent performance. The company has received Outperform and Buy ratings, with price targets of $24 and $26.
The bullish analyst ratings and high price targets suggest a positive outlook for Neumora Therapeutics, despite the recent drop in stock price. The company's lead drug for MDD is seen as promising, which could drive the stock price up in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100